Treatment of stable angina

Current Opinion in Cardiology

Volumn 14, Issue 4, 1999, Pages 349-358

  Thadani, Udho ^a,b  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b Cardiovascular Section   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIANGINA PECTORIS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LIPID; NITRATE;

ANGINA PECTORIS; CORONARY ARTERY; CORONARY ARTERY ATHEROSCLEROSIS; COUNTERPULSATION; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; PRIORITY JOURNAL; REVIEW; SMOKING CESSATION; SPINAL CORD STIMULATION; SYMPATHECTOMY; SYMPTOM;

ANGINA PECTORIS; ANIMALS; DRUG THERAPY, COMBINATION; HUMANS; MYOCARDIAL ISCHEMIA;

EID: 0032767504     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-199907000-00011     Document Type: Review

References (116)

1. 1 Braunwald E, Sobel B: Coronary blood flow and myocardial ischemia. In Heart Disease: a Textbook of Cardiovascular Medicine. Edited by Braunwald E. Philadelphia: WB Sanders; 1988:1191-1221.
2. 2 Thadani U: Medical therapy of stable angina pectoris. Cardiol Clin 1991, 9(1):73-88.
3. 3 Thadani U, Chohan A: Chronic stable angina pectoris: strategies for effective drug therapy. Postgrad Med 1995, 98(6):175-188.
4. 4 Gage JE, Jess DM, Murakami T, Ritter M, Grimm J, Krayen Buehl HP: Vasoconstriction of stenotic coronary arteries during dynamic exercise in patients with classic angina pectoris: reversibility by nitroglycerin. Circulation 1986, 73:865-871.
5. 5 Werns SW, Walton JA, Hsia HH, Nabel EG, Sanz ML, Pitt B, et al.: Evidence of endothelial dysfunction in angiographically normal coronary arteries of patients with coronary artery disease. Circulation 1989, 79:287-291.
6. 6 Asirvatham S, Sebastian C, Thadani U: Choosing the most appropriate treatment for table angina safety: safety considerations. Drug Safety 1998, 19:23-44. This review focuses on the management of patients with stable angina, with emphasis of choosing appropriate therapy by considering comorbid conditions and adverse effects of therapy.
7. 7 Mulcahy D, Husain S, Zalos G, Rehman A, Andrew NP, Schenk WH, et al.: Ischemia during ambulatory monitoring as a prognostic indicator in patients with stable coronary artery disease. JAMA 1997, 277(4):318-324.
8. 8 Deedwania P: Is there evidence in support of the ischemia suppression hypothesis? J Am Coll Cardiol 1994, 24(1):21-24.
9. 9 Rogers WJ, Bourassa MG, Andrews TC, Bertolei BD, Blumenthal RS, Chaitman BR: Asymptomatic Cardiac Ischemia Pilot (ACIP) Study: outcome at 1 year for patients with asymptomatic cardiac ischemia randomized to medical therapy or revascularization. J Am Coll Cardiol 1995, 25:594-605.
10. 10 Mulcahy D, Gunning M, Knight C, Patel D, Davies M, Underwood B, et al.: Long term (5 year) effects of transient (silent) ischaemia on left ventricular systolic function in stable angina: clinical and radionuclide study. Eur Heart J 1998, 19:1342-1347. This study is the first to suggest that in mildly symptomatic patients in the absence of intervening MI, silent ischemia has no adverse effect on LV function.
11. 11 Pepine CJ, Abrams J, Mark RA, Morris JJ, Scheidt SS, Handberg E, et al.: Characteristics of a contemporary population with angina pectoris. TIDES Investigators. Am J Cardiol 1994, 74:226-231.
12. 12 Thadani U: Management of patients with chronic stable angina at low risk for serious cardiac events. Am J Cardiol 1997, 79(12B):24-30.
13. 13 Gillum R: Trends in acute myocardial infarction and coronary artery disease death in the United States. J Am Coll Cardiol 1993, 23:7275-7277.
14. 14 Hilton TC, Chaitman BR: The prognosis in stable and unstable angina. Cardiol Clin 1991, 9(1):27-38.
15. 15 The VA Coronary Artery Bypass Surgery Cooperative Study Group: Eighteen year follow up in the Veterans Affairs cooperative study of coronary artery bypass surgery for stable angina. Circulation 1992, 86:121-130.
16. 16 Alderman EL, Bourassa MG, Cohen LS, Davis KB, Kaiser GG, Killip T, et al.: Ten year follow up of survival and myocardial infarction in the randomised coronary artery surgery study. Circulation 1990, 82:1629-1646.
17. 17 Yusuf S, Zucker D, Peduzzi P, Fisher LD, Tarako T, Kennedy JW, et al.: Effect of coronary artery bypass graft surgery on survival: overview of ten year results from randomised trials by the coronary artery bypass graft surgery trialists collaboration. Lancet 1994, 344:563-570.
18. 18 Jackson G: Stable angina: drugs, angioplasty or surgery? Eur Heart J 1997, 18(suppl B):B2-B10.
19. 19 Davies R, Goldberg AD, Forman S, Pepine CJ, Knatterud G, Geller N, et al.: Asymptomatic cardiac ischemia pilot (ACIP) study two year follow up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization. Circulation 1997, 95(8):2037-2043.
20. 20 Pepine CJ, Cohn PF, Deedwania PC, Gibson RS, Handberg E, Hill JA, et al.: Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life: the atenolol silent ischemia study (ASIST). Circulation 1994, 90(2):762-768.
21. 21 Pepine CJ, Levin R: Myocardial ischemia as a target for treatment of patients with chronic coronary artery disease. ACC Current Journal Review 1998, 7:23-27.
22. 22 Doll R, Peto R: Mortality in relation to smoking: 20 year observations on British doctors. BMJ 1976, 2:1526-2536.
23. 23 Willett WC, Green A Spampfer MJ, Spieze E, Colditz GA, Rosner B, et al.: Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. N Engl J Med 1987, 317:1303-1309.
24. 24 Food and Drug Administration: Acetylsalicyclic acid and the heart. JAMA 1993, 270:2669.
25. 25 Fuster V, Dyken ML, Vokonas PS, Hennekens C: Aspirin as a therapeutic agent in cardiovascular disease. Circulation 1993, 87:659-675.
26. 26 Swedish Angina Pectoris Aspirin Trial Group, Juul-Moller S, Edvardson N, Jahnmatz B, Rosen A, et al.: Double blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 1992, 340:1421-1425.
27. 27 Ridker PM, Manson JE, Gaziano M, Buring JE, Hennekens CH: Low dose aspirin therapy for chronic stable angina, a randomised, placebo controlled trial. Ann Intern Med 1991, 114:835-839.
28. 28 Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease, the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
29. 29 Carbajal EV, Deedwania PC: Contemporary approaches in medical management of patients with stable coronary artery disease. Med Clin North Am 1995, 79:1063-1084.
30. 30 Sixth report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure (JNC VI). Arch Intern Med 1997, 157:2413-2446.
31. 31 Grodstein F, Stampfer JM, Colditz GA, Whilett WC, Manson JE, Joff M, et al.: Postmenopausal hormone therapy and mortality. N Engl J Med 1997, 336:1769-1775.
32. 32 Sorensen KE, Dorup I, Hermann AP, Mosekilde L: Combined hormone replacement therapy does not protect women against the age-related decline in endothelium dependent vasomotor function. Circulation 1998, 97:1234-1338.
33. 33 Vogel RA, Corretti MC: Estrogens, progestins and heart disease: can endothelial function divine the benefit. Circulation 1998, 97:1223-226.
34. 34 Peduzzi P, Kamina A, Detre K, for the VA Coronary Artery Bypass Surgery Cooperative Study Group: Twenty-two-year follow-up in the VA cooperative study of coronary artery bypass surgery for stable angina. Am J Cardiol 1998, 81:1393-1399. This study shows that bypass surgery does not improve long-term survival or reduce the incidence of MI compared with medical treatment in patients with stable angina pectoris.
35. 35 Myers WD, Blacksone EH, Davis K, Foster E, Kaiser G: CASS Registry: long term surgical survival. J Am Coll Cardiol 1999, 33:488-498.
36. 36 Hartigan PM, Giacomini JC, Folland ED, Parisi AF, for VA Cooperative Studies Program ACME Investigators: Two-to three-year follow-up of patients with single-vessel coronary artery disease randomized to PTCA or medical therapy (results of a VA cooperative study). Am J Cardiol 1998, 82:1445-1450. In this study, long-term survival is similar in medical and percutaneous transluminal coronary angioplasty groups, although functional improvement was better with percutaneous transluminal coronary angioplasty over 2-year follow-up.
37. 37 RITA-2 Trial Participants: Coronary angioplasty versus medical therapy for angina: the second randomized intervention treatment of angina (RITA-2) trial. Lancet 1997, 350(9076):461-465.
38. 38 Davies RF, Goldberg DA, Forman S, Pepine CJ, Knatterud G, Geller N, et al.: Asymptomatic cardiac ischemia pilot (ACIP) study two-year follow up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization. Circulation 1997, 95(8):2037-2043.
39. 39 Bourassa M, Pepine CJ, Forman SA, Rogers WJ, Dyrda I, Stone PH, et al.: Asymptomatic cardiac ischemia pilot (ACIP) study: effects of coronary angioplasty and coronary artery bypass graft surgery on recurrent angina and ischemia. J Am Coll Cardiol 1995, 26(3) 606-614.
40. 40 The SOLVD investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991, 325:293-302.
41. 41 Pfeffer MA. Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992, 527:669-677.
42. 42 Pepine C: Rationale for ACE inhibition as anti-ischaemic therapy. Eur Heart J 1998, 19:G34-G40.
43. 43 Koh KK, Bui MM, Hathaway L, Gyorgy C, Waclawiw MA, Panza JA, et al.: Mechanism by which quinapril improves vascular function in coronary artery disease. Am J Cardiol 1999, 83:327-331.
44. 44 Pitt B, Dinsmore RE, Lees RS, et al., for the QUIET Study: Angiotensin converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. Am J Cardiol 1999, 83:43-47.
45. 45 Pepine CJ: Ongoing clinical trials of angiotensin-converting enzyme inhibitors for treatment of coronary artery disease in patients with preserved left ventricular function. J Am Coll Cardiol 1996, 27:1048-1052.
46. 46 Goldstein S: Betablockers in hypertensive and coronary heart disease. Arch Intern Med 1996, 156:1267-1276.
47. 47 Opie LH, Sonnenblick EH, Frishman W, Thadani U: Beta blocking agents. In Drugs for the Heart, 4th edn. Edited by Opie LH. Philadelphia: WB Saunders; 1995:1-27.
48. 48 Deedwania P, Carbajal EV: Role of beta blockade in the treatment of myocardial ischemia. Am J Cardiol 1997, 80 (9B):23J-28J.
49. 49 Stables R, Sigwart U: Advances in coronary stenting. ACC Current Journal Review 1998, 7:27-30.
50. 50 Stephens NG, Parsons A, Schofield PM, Jekkt FM, Cheesman K, Mitchinson M: Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996, 347:781-786.
51. 51 Rapola JM, Virtamo J, Ripatti S, Hankka JK, Huttunen JK, Albanes D, et al.: Effect of α tocophenol and β carotene supplements on symptoms, progression and prognosis of angina pectoris. Heart 1998, 79:454-458.
52. 52 Thadani U, Opie LH: Nitrates. In Drugs for the Heart, 4th edn. Edited by Opie LH. Philadelphia: WB Saunders; 1995:31-48.
53. 53 Thadani U: Role of nitrates in angina pectoris. Am J Cardiol 1992, 70:43B-53B.
54. 54 Thadani U, Fung HL, Darke AC, Parker JD: Oral isosorbide dinitrate in angina pectoris: comparison of duration of action and dose response relation during acute and sustained therapy. Am J Cardiol 1982, 49:411-419.
55. 55 Parker JO, Van Koughnett KA, Fung HL: Transdermal isosorbide dinitrate in angina pectoris. Am J Coll Cardiol 1984, 54:8-13.
56. 56 Thadani U, Lipicky RJ: Short and long acting oral nitrates for stable angina pectoris. Cardiovasc Drugs Ther 1994, 8:611-623.
57. 57 Thadani U, Lipicky RJ: Ointments and transdermal nitroglycerin patches for stable angina pectoris. Cardiovasc Drugs Ther 1994, 8:625-633.
58. 58 Thadani U: Nitrate tolerance, rebound and their clinical relevance in stable angina pectoris, unstable angina and heart failure. Cardiovasc Drugs Ther 1996, 10:735-742.
59. 59 Thadani U: Strategies for avoiding nitrate tolerance in stable angina patients. Cardio August 1994, 45-47.
60. 60 Chrysant SG, Glasser SP, Bittar N, Shadid FE, Demisa K, Ibrahim R, et al.: Efficacy and safety of extended release isosorbide mononitrate for stable effort angina pectoris. Am J Cardiol 1993, 72:1249-1256.
61. 61 Parker JO: The Isosorbide-5-Mononitrate Study Group: eccentric dosing with isosorbide-5-mononitrate in angina pectoris. Am J Cardiol 1993, 72:871-876.
62. 62 Thadani U, Maranda CR, Amsterdam E, Spaccavento L, Friedman RG, Chornoff R, et al.: Lack of pharmacologic tolerance and rebound angina pectoris during twice daily therapy with isosorbide-5-mononitrate. Ann Intern Med 1994, 120:353-359.
63. 63 Thadani U: Assessment of "optimal" beta-blockade in treating patients with angina pectoris. Acta Med Scand Suppl 1985, 694:179-187.
64. 64 Weiss R, Ferry D, Pickering E, Smith K, Dennish S, King-Gourley S, et al.: Effectiveness of three different doses of carvedilol for exertional angina. Am J Cardiol 1998, 82:927-931.
65. 65 Van der Does R, Hauf-Zachariou U, Pfarr E, Holtbrügge W, Konig S, Griffiths N, et al.: Comparison of safety and efficacy of carvedilol and metoprolol in stable angina pectoris. Am J Cardiol 1999, 83:643-649.
66. 66 Tzivoni D, Medina A, David D, Barzilai Y, Brunel P: Effect of metoprolol in reducing myocardial ischemic threshold during exercise and during daily activity. Am J Cardiol 1998, 81:775-777.
67. 67 Fox KM, Mulcahy D, Findlay I, Ford I, Dargie HJ, on behalf of the TIBET Study Group: The total ischaemic burden European trial (TIBET): effect of atenolol, nifedipine SR and their combination on exercise test and the total ischemic burden in 608 patients with stable angina. Eur Heart J 1996, 17:96-103.
68. 68 Darjie HJ, Ford I, Fox KM, on behalf of the TIBET Study Group: Effect of ischemia and treatment with atenolol, nifedipine SR and their combination on outcomes in patient with chronic stable angina. Eur Heart J 1996, 17:104-112.
69. 69 Andrews T, Parker JD, Jacobs S, et al.: Effects of therapy with nifedipine GITS or atenolol on mental stress-induced ischemic left ventricular dysfunction. JACC 1998, 32(6):1680-1686.
70. 70 Weber F, Schneider H, Von Armin T, Urbaszek W, for the TIBBS Investigators Group: Heart rate variability and ischemia in patients with coronary hear disease and stable angina pectoris: influence of drug therapy and prognostic value. Eur Heart J 1998, 19:38-50. This interesting study examines the usefulness of heart rate variability and the effects of treatment on prognosis.
71. 71 Opie LH: Calcium channel antagonists in the treatment of coronary artery disease: fundamental pharmacological properties relevant to clinical use. Prog Cardiovasc Dis 1996, 38(4), 273-290.
72. 72 Opie LH, Frishman WH, Thadani U: Calcium channel antagonists (calcium entry blockers). In Drugs for the Heart, 4th edn. Edited by Opie LH. Philadelphia: WB Saunders; 1995, 50-82.
73. 73 Conti CR: The calcium antagonist scare in America: What have we learned? Clin Cardiol 1996, 19:345-346.
74. 74 Thadani U, Glasser S, Bittar N, Beach CL, the Diltiazem CD Study Group et al.: Dose-response evaluation of once-daily therapy with a new formulation of diltiazem for stable angina pectoris. Am J Cardiol 1994, 74:9-17.
75. 75 Rehnqist N, Hjemdahl P, Billing E, Björkander I, Eriksson SV, Forslund L, et al.: Effect of metoprolol versus verapamil in patients with stable angina pectoris. The angina prognosis study in Stockholm (APSIS). Eur Heart J 1996, 17:76-81.
76. 76 Tzivoni D, Kadr H, Braat S, Rutsch W, Ranires JA, Korbin I, et al.: Efficacy of mibefradil compared with amlodipine in suppressing exercise induced and daily silent ischemia: results of multicenter, placebo controlled trial. Circulation 1997, 96:2557-2567.
77. 77 Taylor SH: The efficacy of amlodipine in myocardial ischemia. Am Heart J 1989, 118:1123-1130.
78. 78 Pepine CJ, Faich G, Makuch R: Verapamil use in patients with cardiovascular disease: an overview of randomized trials. Clin Cardiol 1998, 21:633-641. This is a good review of published results with veraparnil.
79. 79 Frishman WH, Glasser S, Stone P, Deedwania PC, Johnson M, Fakouhi D. et al.: Comparison of controlled onset, extended release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. Am J Cardiol 1999, 83:507-514.
80. 80 Deedwania P, the Amlodipine Study Group: Anti-ischemic effects of amlodipine in patients with stable angina pectoris and myocardial ischemia during daily life. Am J Cardiol 1999, 83:1117-1119.
81. 81 Steffensen R, Melchior T, Bech J, Nissen H, Haastrup B, Grande P, et al.: Effects of amlodipine and isosorbide dinitrate on exercise induced and ambulatory ischemia in patients with chronic stable angina pectoris. Cardiol Drugs Ther 1997, 11:629-635.
82. 82 Strauss WE, Parisi AF: Combined use of calcium channel and betablockers for the treatment of stable angina, rationale, efficacy and adverse effects. Ann Intern Med 1988, 109:570-575.
83. 83 Packer M, Drug therapy: combined beta adrenergic and calcium entry blockade in angina pectoris. N Engl J Med 1989, 320:709-713.
84. 84 Thadani U: Combination therapy for the angina patient. J Am Coll Cardiol 1989, 5:15-19.
85. 85 Tolins M, Weir EK, Chesler E, Pierpont GL: Maximal drug therapy is not necessarily optimal in chronic angina pectoris. J Am Coll Cardiol 1984, 4:1051-1057.
86. 86 Akhras, F, Jackson G: Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina. Lancet 1991, 338:1036-1039.
87. 87 Thadani U: Combination therapy. ACC Gurr J Rev 1997, 6:24-25.
88. 88 Task Force of the European Society Cardiology: Management of stable angina pectoris: recommendations of the Task Force of the European Society Cardiology. Eur Heart J 1997, 18:394-413.
89. 89 Dunselman P, van Kempen L, Bouwens L, Holwerda KJ, Merweijer AH, Bernink PILM, et al.: Value of the addition of amlodipine to atenolol in patients with angina pectoris despite adequate beta blockade. Am J Cardiol 1998,, 81:128-132.
90. 90 Knight CJ, Fox K, on behalf of the centralized European studies in angina research (CESAR) investigators: Amlodipine versus diltiazem as additional antianginal treatment to atenolol. Am J Cardiol 1998, 81:133-136.
91. 91 Frishman WH, Bittar N, Glasser S, Habib G, Smith N, Pordy R, et al.: Additional antianginal and anti-ischemic efficacy of mibefradil in patients concomitantly treated with long acting nitrates for chronic stable angina pectoris. Clin Cardiol 1998, 21:483-490.
92. 92 Tzivoni D, Klein J: Improvement of myocardial ischaemia by lipid lowering drugs. Eur Heart J 1998, 19:230-234. This study summarizes results of lipid lowering therapy in various ischemic syndromes.
93. 93 Van Boven AJ, Jukema JW, Zwinderman AH, Crijns HJGM, Lie KI, Bruschke AVS, on behalf of the Regress Study Group: Reduction transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. Circulation 1996, 94(7):1503-1505.
94. 94 Andrews TC, Raby K, Barry J, Najmi CL, Allred E, Ganz P, et al.: Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation 1997, 95:324-328.
95. 95 Ikram H, Low CJS, Shirlaw TM, Foy SG, Grozier IH, Richards AK, et al.: Angiotensin converting enzyme inhibition in chronic stable angina: effect on myocardial ischemia and comparison with nifedipine. Br Heart J 1994, 71:30-33.
96. 96 Rosano GMC, Sarrel PM, Pool-Wilson PA, Collins P: Beneficial effect of estrogen on exercise-induced myocardial ischemia in women with coronary artery disease. Lancet 1993, 342:133-136.
97. 97 Al-Khalili F, Landgren BM, Eksborg S, Franco-Cereceda A, Schen CK, Gustafsson K, et al.: Does sublingual 17β-oestradiol have any effects on exercise capacity and myocardial ischaemia in post-menopausal women with stable coronary artery disease? Eur Heart J 1998, 19:1019-1026. This study failed to confirm beneficial effects of estrogen on exercise tolerance and myocardial ischemia in postmenopausal women with stable angina.
98. 98 Webb CM, Adamson DL, de-Zeigler D, Collins P: Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Am J Cardiol 1999, 83:437-439.
99. 99 Rosano GMC, Leonardo F, Pagnotta P, Pelliccia F, Panina G, Cerquetani E, et al.: Acute anti ischemic effect of testosterone in men with coronary artery disease. Circulation 1999, 99:1666-1670.
100. 100 Meany TB, Richardson P, Camm AJ, Coltart J, Griffith M, Maltz M, et al.: Exercise capacity after single and twice-daily doses of nicorandil in chronic stable angina pectoris. Am J Cardiol 1989, 63:66J-70J.
101. 101 Thadani U, Strauss W, Glasser SP, Frishman W, Burger AJ, Locker PK, et al.: Evaluation of antianginal and anti ischemic efficacy of nicorandil: results of a multicenter study [abstract]. J Am Coll Cardiol 1994, 23:267A.
102. 102 Rajaratnam R, Brieger D, Hawkins R. Freedman S: Attenuation of antiischemic efficacy during therapy with nicorandil in patients with stable angina pectoris. Am J Cardiol 1999, 83:1120-1124.
103. 103 Brown CM, Clarke B, Dye A, Fraser S, Kenny BA, Kirkpatric AT, et al.: Pharmacological profile of ranolozine, a metabolic modulator active in ischemia (abstract). Br J Pharmacol 1988, 23(suppl):248.
104. 104 Jain D, Dasgupta P, Hughes LO, Lahiria, Rafferty EG: Ranolazine (RS-43285) a preliminary study of a new antianginal agent with selective effect on ischemic myocardium. Eur J Clin Pharmacol 1990, 38:111-114.
105. 105 Thadani U, Ezekowitz M, Fenney L, Chiang Y-K, for the Ranolazine Study Group: Double blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Circulation 1994, 90:726-734.
106. 106 Desideri A, Celegon L: Metabolic management of ischemic heart disease: clinical data with trimetazidine. Am J Cardiol 1998, 82;50K-53K.
107. 107 Tanaka T, Fujita M, Nakae I, Tamaki SI, Hasegawa K, Kihara Y, et al.: Improvement of exercise capacity by sarpogvvelate as a result of augmented collateral circulation in patients with effort angina. J Am Coll Cardiol 1998, 32:1982-1986.
108. 108 Quyyumi AA: Does acute improvement of endothelial dysfunction in coronary artery disease improve myocardial ischemia? A double blind comparison of parenteral D-and L-arginine. J Am Coll Cardiol 1998, 32:904-911.
109. 109 Hughes GC, Landolfo KP, Lowe JE, Coleman RB, Donovan CL: Perioperative morbidity and mortality after transmyocardial laser revascularization: incidence and risk factors for adverse events. J AM Coll Cardiol 1999, 33:1021-1026.
110. 110 Burns SM, Sharples LD, Tait S, Caine N, Wallwork J, Schofield PM, et al.: The transmyocardial laser revascularization international registry report. Eur Heart J 1999, 20:31-37.
111. 111 Nagele H, Stubbe H, Nienaber C, Rodiger W: Results of transmyocardial laser revascularization in non-revasularizable coronary artery disease after 3 years follow up. Eur Heart J 1998, 19:1525-1530. In this study, optimization of medical treatment is found to lead to control of symptoms, even in refractory patients.
112. 112 Cohn PF, Lawson WE: Role of enhanced external counterpulsation in chronic angina pectoris. Am J Cardiol 1995, 75:840-841.
113. 113 Lawson W, Hui JCK, Zheng ZS, Burger L, Jaing L, Lillis D, et al.: Improved exercise tolerance following enhanced external counterpulsation: cardiac or peripheral effect. Cardiology 1996, 87:271-275.
114. 114 Soran O, Crawford LE, Schneider VM, Feldman AM: Enhanced external counterpulsation in the management of patients with cardiovascular disease. Clin Cardiol 1999, 22:173-178. Enhanced external counterpulsation as an adjunct therapy was useful in management of patients with stable angina pectoris.
115. 115 Mannheimer C, Eliasson T, Augustinsson LE, Blomstrand C, Emanuelsson H, Larsson S, et al.: Electrical stimulation versus coronary artery bypass surgery in severe angina pectoris: the ESBY study. Circulation 1998, 97:1157-1163. In this study, spinal cord stimulation is as effective as coronary bypass surgery.
116. 116 Jessurun GAJ, Tio RA, De Jongste MJL, Hautvast RWK, Heijer PD, Crijus HJGM, et al.: Coronary blood flow dynamics during transcutaneous electrical nerve stimulation for stable angina pectoris associated with severe narrowing of one major coronary artery. Am J Cardiol 1998, 82:921-926.